|
Characteristics
|
1998a
|
2004
|
2007
|
|---|
| |
n (%)
|
χ2
|
OR
|
p
|
n (%)
|
χ2
|
OR
|
p
|
n (%)
|
χ2
|
OR
|
p
|
|---|
| | |
(p-value)
|
(95%CI)b
| | |
(p-value)
|
(95%CI)
| | |
(p-value)
|
(95%CI)
| |
|---|
|
Age at diagnosis, years
|
|
≥40
|
228 (81.1)
|
9.16 (<0.01)
|
0.4 (0.2-0.8)
|
<0.01
|
160 (74.4)
|
6.30 (0.01)
|
0.5 (0.2-0.9)
|
0.03
|
186 (72.1)
|
16.86 (<.0001)
|
0.4 (0.2-0.7)
|
<0.01
|
|
<40
|
53 (18.9)
| |
1 (referent)
| |
55 (25.6)
| |
1 (referent)
| |
72 (27.9)
| |
1 (referent)
| |
|
Gender
|
|
Male
|
166 (59.1)
|
0.00 (0.95)
|
0.8 (0.4-1.7)
|
0.60
|
126 (58.6)
|
1.25 (0.26)
|
0.7 (0.4-1.3)
|
0.26
|
151 (58.5)
|
0.49 (0.49)
|
1.4 (0.8-2.3)
|
0.29
|
|
Female
|
115 (40.9)
| |
1 (referent)
| |
89 (41.4)
| |
1 (referent)
| |
107 (41.5)
| |
1 (referent)
| |
|
Charlson comorbidity score
|
|
≥1
|
101 (35.9)
|
0.00 (0.97)
|
1.2 (0.6-2.4)
|
0.71
|
118 (54.9)
|
3.71 (0.05)
|
0.6 (0.4-1.2)
|
0.13
|
140 (54.3)
|
20.36 (<.0001)
|
0.4 (0.2-0.6)
|
<0.001
|
|
=0
|
180 (64.1)
| |
1 (referent)
| |
97 (45.1)
| |
1 (referent)
| |
118 (45.7)
| |
1 (referent)
| |
|
CML severity
|
|
high severity
|
45 (16.0)
|
17.90 (<.0001)
|
4.3 (2.0-9.3)
|
<0.001
|
28 (13.0)
|
1.64 (0.20)
|
2.1 (0.8-5.4)
|
0.12
|
40 (15.5)
|
2.87 (0.09)
|
2.3 (1.1-5.1)
|
0.04
|
|
less severity
c
|
236 (84.0)
| |
1 (referent)
| |
187 (87.0)
| |
1 (referent)
| |
218 (84.5)
| |
1 (referent)
| |
- a. 1998 (beginning of study, n = 281); 2004 (end of prior authorization request for imatinib use, n = 215); 2007 (end of study, n = 258).
- b. OR = odds ratio, each OR of the variable was adjusted by the other factors in the logistic regression model.
- c. Less severity, including moderate, low severity or missing relevant severity information (unknown).
